Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate

2,6-二磷酸果糖激活细胞周期蛋白依赖性激酶

基本信息

  • 批准号:
    8448296
  • 负责人:
  • 金额:
    $ 29.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB) phosphorylate fructose-6-phosphate (F6P) to fructose-2,6-bisphosphate (F2,6BP), which is an allosteric activator of 6-phosphofructo-1-kinase, a rate-limiting enzyme in the glycolytic pathway. Although there are four PFKFB enzymes, PFKFB3 and PFKFB4 are of particular interest since these enzymes have been found to be activated in human cancers, to be increased by hypoxic exposure via HIF-1?, and, in the case of PFKFB3, to be required for the growth of Ras-transformed tumors. In order to better understand the relative contributions of PFKFB2-4 to glycolysis, we examined the subcellular localization of these enzymes and were surprised to find that whereas PFKFB2 and PFKFB4 localized to the cytoplasm (the site of glycolysis), PFKFB3 localized to the nucleus. We then over-expressed PFKFB3 in HeLa cells and observed no change in glucose uptake but rather an increase in proliferation. Eukaryotic cell division is controlled by cyclin dependent kinases (CDKs) that bind to regulatory cyclins and phosphorylate hundreds of substrates that control DNA replication, transcription and mitosis. We found that over-expression of PFKFB3 stimulated CDK1 activity in HeLa cells and that purified F2,6BP stimulated recombinant monomeric CDK1 in vitro. We then confirmed the requirement of CDK1 for the pro-proliferative effects of PFKFB3 by demonstrating that CDK1 siRNA but not CDK2, CDK4 or CDK6 siRNA reversed the increased proliferation caused by over-expression of PFKFB3. Importantly, transfection of HeLa cells with PFKFB3-specific siRNA decreased endogenous PFKFB3 which in turn reduced CDK1 activity, increased p27 expression, suppressed G1/S transition, induced apoptosis but had no impact on glucose uptake. These data support a distinct role for PFKFB3 in the regulation of cell cycle progression and apoptosis, and not glucose metabolism. We propose to test the hypothesis that nuclear F2,6BP generated by PFKFB3 activates CDKs and promotes cell cycle progression. We anticipate that nuclear F2,6BP may serve unique roles in regulating CDK1, and other CDKs, and that inhibition of PFKFB3 will suppress CDK activities without significantly affecting glucose metabolism in transformed but not in normal cells.
描述(由申请人提供):6-磷酸果-2-激酶/果糖-2,6-磷酸酶(PFKFB)磷酸化磷酸胶质果糖-6-磷酸(F6P)至果糖-2,6-磷酸果实(F2,6bp),这是6-磷酸胶质电量的分配率,是一种分配率糖酵解途径。尽管有四种PFKFB酶,但PFKFB3和PFKFB4特别令人感兴趣,因为已经发现这些酶在人类癌症中被激活,并且通过HIF-1?通过HIF-1?的低氧暴露来增加,而对于PFKFB3,对于Ras传输的RAS传输tumors的生长所必需。 In order to better understand the relative contributions of PFKFB2-4 to glycolysis, we examined the subcellular localization of these enzymes and were surprised to find that whereas PFKFB2 and PFKFB4 localized to the cytoplasm (the site of glycolysis), PFKFB3 localized to the nucleus.然后,我们在HeLa细胞中过度表达的PFKFB3,观察到葡萄糖摄取没有变化,而是增殖的增加。真核细胞分裂受细胞周期蛋白依赖性激酶(CDK)的控制,这些激酶(CDKS)与调节性细胞周期蛋白结合并磷酸化数百个控制DNA复制,转录和有丝分裂的底物。我们发现,PFKFB3的过表达刺激了HeLa细胞中的CDK1活性,并且在体外纯化了F2,6bp刺激了重组单体CDK1。然后,我们通过证明CDK1 siRNA而不是CDK2,CDK4或CDK6 siRNA证实了CDK1对PFKFB3促生殖作用的需求,这反转了PFKFB3过表达引起的增殖增加。重要的是,用PFKFB3特异性siRNA转染HeLa细胞降低了内源性PFKFB3,进而降低CDK1活性,p27表达增加,抑制G1/s转变,诱导凋亡,但对葡萄糖摄取没有影响。这些数据支持PFKFB3在调节细胞周期进程和凋亡的调节中的独特作用,而不是葡萄糖代谢。我们建议检验以下假设:PFKFB3产生的核F2,6bp激活CDK并促进细胞周期进程。我们预计核F2,6bp可能在调节CDK1和其他CDK中起独特的作用,并且抑制PFKFB3会抑制CDK活性,而不会显着影响正常细胞转化但不影响正常细胞中的葡萄糖代谢。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jason A. Chesney其他文献

Jason A. Chesney的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jason A. Chesney', 18)}}的其他基金

Leveraging Zika virus driven myeloid cell responses to treat GBM
利用寨卡病毒驱动的骨髓细胞反应来治疗 GBM
  • 批准号:
    10891973
  • 财政年份:
    2023
  • 资助金额:
    $ 29.26万
  • 项目类别:
TBD
待定
  • 批准号:
    10833940
  • 财政年份:
    2023
  • 资助金额:
    $ 29.26万
  • 项目类别:
TBD
待定
  • 批准号:
    10765267
  • 财政年份:
    2023
  • 资助金额:
    $ 29.26万
  • 项目类别:
Center for Cancer Immunology and Immunotherapy (CCII)
癌症免疫学和免疫治疗中心 (CCII)
  • 批准号:
    10753949
  • 财政年份:
    2020
  • 资助金额:
    $ 29.26万
  • 项目类别:
Surveillance and identification of variants of concern within circulating SARS-CoV-2 across Kentucky
肯塔基州流行的 SARS-CoV-2 中值得关注的变种的监测和鉴定
  • 批准号:
    10381183
  • 财政年份:
    2020
  • 资助金额:
    $ 29.26万
  • 项目类别:
Center for Cancer Immunology and Immunotherapy (CCII)
癌症免疫学和免疫治疗中心 (CCII)
  • 批准号:
    10577763
  • 财政年份:
    2020
  • 资助金额:
    $ 29.26万
  • 项目类别:
Center for Cancer Immunology and Immunotherapy (CCII)
癌症免疫学和免疫治疗中心 (CCII)
  • 批准号:
    10333205
  • 财政年份:
    2020
  • 资助金额:
    $ 29.26万
  • 项目类别:
Center for Cancer Immunology and Immunotherapy (CCII)
癌症免疫学和免疫治疗中心 (CCII)
  • 批准号:
    10093098
  • 财政年份:
    2020
  • 资助金额:
    $ 29.26万
  • 项目类别:
Surveillance and identification of variants of concern within circulating SARS-CoV-2 across Kentucky
肯塔基州流行的 SARS-CoV-2 中值得关注的变种的监测和鉴定
  • 批准号:
    10595227
  • 财政年份:
    2020
  • 资助金额:
    $ 29.26万
  • 项目类别:
Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate
2,6-二磷酸果糖激活细胞周期蛋白依赖性激酶
  • 批准号:
    8250362
  • 财政年份:
    2011
  • 资助金额:
    $ 29.26万
  • 项目类别:

相似国自然基金

miRNA-454靶向Stat3调控PFKFB3在腹膜血管新生中的作用机制研究
  • 批准号:
    81900697
  • 批准年份:
    2019
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
Notch1/PFKFB3调控EPCs糖酵解途径参与胎盘血管形成的作用及机制研究
  • 批准号:
    81873844
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    面上项目
PFKFB3调控单核/巨噬细胞能量代谢重编程在动脉粥样硬化中的作用及机制
  • 批准号:
    81700395
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
内皮细胞6-磷酸果糖-2激酶(亚型3)对肥胖和胰岛素敏感性的调控研究
  • 批准号:
    81400826
  • 批准年份:
    2014
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Inflammation and retinopathy of prematurity
早产儿炎症和视网膜病变
  • 批准号:
    10610870
  • 财政年份:
    2019
  • 资助金额:
    $ 29.26万
  • 项目类别:
Inflammation and retinopathy of prematurity
早产儿炎症和视网膜病变
  • 批准号:
    9918406
  • 财政年份:
    2019
  • 资助金额:
    $ 29.26万
  • 项目类别:
Inflammation and retinopathy of prematurity
早产儿炎症和视网膜病变
  • 批准号:
    10397044
  • 财政年份:
    2019
  • 资助金额:
    $ 29.26万
  • 项目类别:
Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate
2,6-二磷酸果糖激活细胞周期蛋白依赖性激酶
  • 批准号:
    8250362
  • 财政年份:
    2011
  • 资助金额:
    $ 29.26万
  • 项目类别:
Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate
2,6-二磷酸果糖激活细胞周期蛋白依赖性激酶
  • 批准号:
    8636908
  • 财政年份:
    2011
  • 资助金额:
    $ 29.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了